GHRP-2 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

GHRP-2 for Health & Longevity

Created on 07/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A lab-made peptide that copies the hunger hormone ghrelin and reliably triggers a short pulse of the body's own growth hormone. That single effect is well documented, but evidence for real benefits like more muscle, less fat, or longer health is thin. It lowers insulin sensitivity, raises appetite, and its long-term value and safety remain unproven. (Full Review)

Protocol

Standard Dosing
~100 mcg per dose
Subcutaneous injection, 1–3 times daily; 200–300 mcg total daily is common.
Timing
Bedtime, empty stomach
Extra doses in the morning and post-exercise; food blunts the GH response.
Dosing Pattern
Split dosing
Multiple small injections mimic the body's natural pulsatile GH pattern.
Time to effect
Growth Hormone Pulse
Within minutes
GH pulse is immediate after dosing; subsides toward baseline within 2–3 hours.
Body Composition
Weeks to months
Downstream body-composition changes, if they occur, take weeks to a few months of consistent use.
[time_3_label]
[time_3_value]
[time_3_sub]

Benefits

Contraindications
  • Active or history of cancer
  • Active diabetic retinopathy
  • Pregnancy or breastfeeding
  • Untreated significant insulin resistance
  • Children outside a formal medical setting
    •
Key Interactions
  • Insulin and glucose-lowering drugs (metformin, sulfonylureas such as glipizide)
  • Corticosteroids and cortisol-raising agents (prednisone, dexamethasone)
  • Thyroid hormone (levothyroxine)
  • Sympathomimetic OTC products (pseudoephedrine)
  • GHRH analogs (sermorelin, CJC-1295, tesamorelin)
  • Other ghrelin-receptor agonists (GHRP-6, hexarelin, ipamorelin, ibutamoren)
  • Supplements affecting glucose or GH (berberine, chromium, alpha-lipoic acid, arginine, ornithine, GABA)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Reduced insulin sensitivity / elevated blood glucose; increased appetite and unwanted weight gain
    •
  • Low: Elevated prolactin and cortisol; water retention, joint pain, and tingling; injection-site reactions
    •
  • Speculative: Theoretical cancer / growth-promotion risk; contamination and dosing errors from gray-market products
    •

Monitoring

Marker Target Why
IGF-1 Upper-normal for age (avoid supra-normal) Primary downstream marker of GH effect and of proliferative/GH-excess risk
Fasting glucose 70–90 mg/dL Detects GHRP-2's insulin-desensitizing effect
HbA1c < 5.4% 3-month average blood sugar; catches sustained glucose rise
Fasting insulin 2–5 µIU/mL Reveals early insulin resistance before glucose rises
Prolactin Within normal reference range GHRP-2 can transiently raise prolactin at higher doses
Morning cortisol Within normal reference range GHRP-2 can transiently raise cortisol
IGFBP-3 Within normal reference range Binding protein that contextualizes IGF-1 levels

Cadence: Baseline, at 4–8 weeks after starting, then every 3–6 months during use.

Qualitative Assessment

  • Sleep quality and depth
  • Energy levels and recovery from exercise
  • Appetite and body-weight trend
  • Body composition (muscle vs. fat), by measurement or imaging
  • Joint comfort and any fluid retention or tingling (early signs of GH excess)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.